INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Derivative conversionVerified data

Frankenius Equity AB reported TLSI

10% Owner · TriSalus Life Sciences, Inc. · TriSalus Life Sciences, Inc. — Series A Convertible Preferred Stock

Side
C
Value
—
Shares
230.0K
Price
—
Executed
Jul 31, 2025
Disclosed
Apr 20, 2026
Disclosure timeline263 days from execution to publication · legal deadline 2 business days
Jul 31 executedApr 20, 2026 disclosed

TLSI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+15 / 15

    Disclosed 187 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TLSI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    ST
    Szela Mary TDirector, CEO and President
    TLSITriSalus Life Sciences, Inc.
    Tax withholding
    		F$12K
    2,693 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    31
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,299
    296 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    31
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,387
    316 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    31
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,427
    325 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    28
    FA
    Frankenius Equity AB10% Owner
    TLSITriSalus Life Sciences, Inc.
    Derivative conversion
    		C—
    759.0K sh
    		Jul 31, 2025Apr 20, 2026
    traded Jul 31, 2025
    		+263dSEC FORM 4

    Evidence

    17
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    80.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    PD
    Patience DavidChief Financial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    65.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    PD
    Patience DavidChief Financial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    130.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    DJ
    Devlin JodiChief of Clinical Operations
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    50.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    40.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    DJ
    Devlin JodiChief of Clinical Operations
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    60.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    120.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    50.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-026014
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jul 31, 2025
    Published
    Apr 20, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Frankenius Equity AB
    Role
    10% Owner
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    TriSalus Life Sciences, Inc. — Series A Convertible Preferred Stock
    Ticker
    TLSI
    Shares
    230.0K
    Price per share
    $0
    Execution date (reported)
    Jul 31, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    263

    What this establishes

    Frankenius Equity AB filed this Form 4 reporting a derivative conversion of TLSI on Jul 31, 2025. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    10% Owner
    Frankenius Equity ABcik:0001988262
    Issuer
    TriSalus Life Sciences, Inc.cik:0001826667

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.